SightfileU.S. market data from official filings

BIOAGE LABS INC (BIOA)

Name: BIOAGE LABS INC (BIOA) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001709941 · EDGAR filings · Updated 2026-07-01

BIOAGE LABS INC (BIOA) has reported institutional ownership of 77.3%, with 144 institutional managers holding positions valued at $599.2M per the latest 13F reporting period.

Institutional ownership

77.3%

Institutional managers

144

Reported 13F value

$599.2M

Insider activity

22 trans.

−$6.06M net selling

Latest updates

2026-07-01 — Insider transaction reported (Form 4)
2026-06-30 — Notice of proposed sale filed (Form 144)
2026-06-29 — Notice of proposed sale filed (Form 144)
2026-06-12 — Insider transaction reported (Form 4)
2026-06-12 — Insider transaction reported (Form 4)
2026-06-12 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, BIOAGE LABS INC has 144 institutional holders and institutional ownership of 77.3%.

Insider activity

Insiders reported 22 transactions (0 buys, 10 sells) across 3 reporting insiders, with a net reported value of −$6.06M.

Related companies

STEVANATO GROUP S P A (STVN) · XERIS BIOPHARMA HOLDINGS INC (XERS) · OMADA HEALTH INC (OMDA) · MEIRAGTX HLDGS PLC (MGTX) · RELMADA THERAPEUTICS INC (RLMD) · ARVINAS INC (ARVN)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-01.